Taken together, these results indicated that anlotinib had excellent antitumor activity in ICC, mainly via inhibiting the phosphorylation level of VEGFR2 and subsequent inactivation of PIK3/AKT signaling. The gene discussed is PIK3CG; the disease is intrahepatic cholangiocarcinoma.